Tags: adverse eventsalyconebendamustinebloodblood cancerbortezomibcancercross trial comparisoncyclophosphamidedexamethasoneelderlygerigeriatrichematologyhemeinductionixazomibmaintenancemaintenance therapyMMmultiple myelomaneuropathynewly diagnosed multiple myelomaoncologyorroverall response rateperipheral neuropathypfspnprogression-free survivalsurvivalthalidomidetolerabilitytransplant ineligibletreatment discontinuationvistawell-tolerated




![2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/Untitled-design-350x250.png)



